Solutions
About Us
Insights
Careers

Webinar – PKBOIN-12 and Project Optimus: Identifying the Optimal Biological Dose

Case Study – Tailoring Statistical Services for Academic Clients and Unlocking Greater Value for Medical Research

White Paper – Optimizing Interim Analyses Considering Potential Enrollment Variations: A Cytel-GSK Trial Design Case Study

White Paper – Navigating the Evolving Landscape of Data Engineering and the Quest for Elusive Talent

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial. Rezelj VV, Paddenburg F, Diegbe ME, Nangosyah J, Reisinger EC, Hu W, Truyers C, Scheper G, Le Gars M, Hendriks J, Struyf F, Douoguih M, Schuitemaker H, Ruiz-Guiñazú J. Vaccines (Basel). 2024

When does adjusting covariate under randomization help? A comparative study on current practices. Gao Y, Liu Y, Matsouaka R. BMC Med Res Methodol. 2024

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2). Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Domingo-Horne R, Toukam M, Nunn A, Maghzi AH, Kuhelj R, Lasky T. Neurol Ther. 2024

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. Kean LS, Burns LJ, Kou TD, Kapikian R, Lozenski K, Langston A, Horan JT, Watkins B, Qayed M, Bratrude B, Betz K, Tang XY, Zhang MJ, Connolly SE, Polinsky M, Gavin B, Gomez-Caminero A, Pasquini MC. Blood. 2024

Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer. Skarping I, Bendahl PO, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Christiansen P, Filtenborg Tvedskov T, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Vrou Offersen B, Olofsson Bagge R, Reimer T, Sund M, Rydén L, de Boniface J. JAMA Surg. 2024

Inhaled Nitric Oxide in Fibrotic Lung Disease: A Randomized, Double-Blind, Placebo-controlled Trial. Nathan SD, Rajicic N, Dudenhofer R, Hussain R, Argula R, Bandyopadhyay D, Luckhardt T, Muehlemann N, Flaherty KR, Glassberg MK, Lancaster L, Raghu G, Fernandes P. Ann Am Thorac Soc. 2024